GrowGeneration reported Q3 2026 financial results, achieving positive GAAP net income of $0.2 million and expanding gross margins to 32.4%. The company also announced a 2026 Restructuring Plan involving the closure of 4-5 underperforming retail locations and workforce reductions to focus on its proprietary-brand business. Full-year 2026 revenue guidance was narrowed to a range of $163 million to $165 million.
Term
Q3 2026
“Our third-quarter results reflect the continued progress of GrowGeneration's transformation into a national commercial cultivation supply and proprietary-brand platform. We delivered $44.8 million in revenue, expanded gross margin to 32.4%, and generated $2.3 million in Adjusted EBITDA.”
Darren Lampert, GrowGen’s Co-Founder and Chief Executive Officer
“We are also continuing to take meaningful actions to improve our cost structure, including a strategic restructuring plan initiated in the fourth quarter. Store and other operating expenses declined approximately 12% year-over-year, and we are moving forward with four to five store closures in the fourth quarter, along with additional restructuring initiatives designed to further reduce fixed costs and improve operating efficiency.”
Darren Lampert, GrowGen’s Co-Founder and Chief Executive Officer
Alto Neuroscience reported financial results for the third quarter ended September 30, 2026, highlighting a cash position of $319.8 million following a $100 million financing. The company confirmed its clinical pipeline remains on track, with topline data for its PACE-1 trial in treatment-resistant depression expected in the second half of 2027.
“During the third quarter, we continued to advance our clinical programs and strengthened our financial position ahead of a milestone-rich 2027. PACE-1 remains on track, and our recent financing has enabled us to expand the ALTO-207 Phase 3 development plans to include both monotherapy and adjunctive trials, aimed at supporting a broad label in TRD.”
Amit Etkin, M.D., Ph.D., founder and chief executive officer
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focusing on the development of CTIM-76 and CT-202, while winding down its CT-95 Phase 1 clinical trial. As of November 6, 2026, the company had 91,879,177 shares of common stock outstanding and is classified as a smaller reporting company and emerging growth company.
Bluerock Homes Trust reported a net loss of $8.48 million for the third quarter of 2026, with total revenues increasing to $19.20 million compared to $16.61 million in the prior year period. The company's total assets stood at $1.17 billion as of September 30, 2026, while it continued to experience net losses attributable to common stockholders of $3.14 million for the quarter.
Resideo Technologies reported Q3 2026 financial results, its first quarter following the spin-off of its ADI Global Distribution business. The company achieved 3% revenue growth to $727 million and used a $900 million dividend from the ADI separation plus cash on hand to repay $1.1 billion in gross debt.
Term
Q3 2026
“Resideo delivered top and bottom line third quarter results that were near the high end of our outlook ranges in our first quarter following the separation of ADI, underscoring our team’s continued strong execution. We achieved 3% revenue growth year-over-year across all sales channels and 6% growth year-over-year excluding OEM Security, driven by customer demand for our differentiated, non-discretionary products.”
Tom Surran, Resideo's President and CEO
“We remain focused on creating value for our customers with our differentiated products and services. That includes new AI-powered capabilities on our next-generation FORTIQ software platform, which delivers actionable intelligence that enhances customer productivity and optimizes the end-user’s experience.”
Kopin Corporation reported Q3 2026 financial results with revenue growing 52% year-over-year to $18.2 million. The company narrowed its operating loss to $0.5 million and highlighted a significant $18.6 million U.S. Army IBAS award for its MicroLED technology.
For the nine months ended September 30, 2026, the REIT reported a net loss of $5.1 million on total revenues of $43.0 million, compared to a net loss of $68,000 on $23.6 million in revenue for the same period in 2025. Total assets grew significantly to $866.4 million from $514.4 million at year-end 2025, driven by increased investments in real estate and real estate-related securities.
For the nine months ended September 30, 2026, EQT Exeter Real Estate Income Trust reported total revenues of $31.0 million and a net loss of $1.5 million. Total assets increased to $557.8 million from $541.3 million at year-end 2025, while the company continued to issue multiple classes of common stock to fund its real estate investment activities.
Revvity, Inc. reported total revenue of $728.9 million for the third quarter of 2026, a 4% increase compared to the same period in 2025. Net income for the quarter rose to $62.3 million, up from $46.7 million year-over-year, while the company continued to execute its share repurchase program, reducing outstanding common stock to approximately 111.6 million shares.
Achieve Life Sciences significantly strengthened its liquidity position, ending September 30, 2026, with $201.5 million in cash and marketable securities compared to $36.4 million at the end of 2025. The company is focused on its NDA resubmission for cytisinicline following a CRL and is currently involved in arbitration with its supplier, Sopharma.
Velo3D, Inc. reported a significant increase in total assets to $252.3 million as of September 30, 2026, driven by a rise in cash and cash equivalents to $75.7 million and a substantial increase in other assets. The company continues to focus on scaling its additive manufacturing solutions, particularly in the defense and aerospace markets, while managing its liquidity and debt obligations.
Chain Bridge Bancorp, Inc. is a bank holding company for Chain Bridge Bank, N.A., specializing in services for political organizations. The filing highlights risks related to deposit seasonality following the November 2026 elections and the company's dual-class stock structure controlled by the Fitzgerald Family.
Bionano Genomics reported total revenue of $8.28 million for the third quarter of 2026, a 12% increase year-over-year, while narrowing its quarterly net loss to $6.45 million compared to $8.50 million in 2025. The company's cash position remains tight, with total cash, cash equivalents, and investments decreasing significantly from $19.27 million at the end of 2025 to $8.17 million as of September 30, 2026.
Electromed, Inc. reported net revenues of $18.7 million for the quarter ended September 30, 2026, a 10.6% increase over the prior year, driven primarily by growth in the homecare market. Net income rose to $2.8 million from $2.1 million, while the company significantly increased its common stock repurchases to $4.3 million during the period.
Carlsmed, Inc. reported revenue of $56.6 million for the nine months ended September 30, 2026, a significant increase from $35.3 million in the prior year period. Despite the revenue growth, the company recorded a net loss of $31.5 million for the first nine months of 2026 as operating expenses, particularly in sales, marketing, and general administration, increased substantially.
Kura Oncology reported total revenue of $22.8 million for Q3 2026, driven by the introduction of $13.9 million in product revenue. Despite this, the company recorded a net loss of $70.2 million for the quarter and $211.9 million for the first nine months of 2026, with total stockholders' equity declining significantly to $18.0 million from $174.1 million at year-end 2025.
Atara Biotherapeutics reported Q3 2026 financial results, highlighting a significant 83% year-over-year reduction in operating expenses and a net loss of $2.2 million. The company is focused on the FDA's March 31, 2027, PDUFA date for tab-cel, which if approved would trigger a $31 million milestone payment from Pierre Fabre Laboratories.
“The resubmission of the tab-cel BLA was an important milestone this quarter, and we remain focused on supporting Pierre Fabre Pharmaceuticals (PFP) toward a successful outcome. We continue to believe in tab-cel’s significant commercial potential in the U.S. In parallel, we are taking steps to control expenses with the goal of protecting and maximizing shareholder value while enhancing our strategic flexibility.”
Cokey Nguyen, President and Chief Executive Officer
Intelligent Protection Management Corp. reported Q3 2026 revenue of $11.0 million, a 75% increase year-over-year, driven by strong demand for cybersecurity and cloud infrastructure procurement. The company generated $5.6 million in operating cash flow and noted a 33% increase in core managed services revenue from non-affiliated customers.
Term
Q3 2026
“Financial results for the third quarter of 2026 reflected exceptional customer demand and continued execution of our growth strategy, resulting in total revenue increasing more than 75% to approximately $11.0 million compared to the third quarter of 2025.”
Jason Katz, Chairman and Chief Executive Officer
“Our balance sheet remains strong, providing the financial flexibility necessary to support organic growth initiatives while pursuing strategic opportunities that enhance our long-term growth profile.”
LightPath Technologies reported fiscal 2027 first quarter revenue of $20.8 million, a 38% year-over-year increase driven by a shift toward higher-value cameras and optical assemblies. The company achieved a record order backlog of $132.9 million and generated its fifth consecutive quarter of positive adjusted EBITDA. During the period, the company also completed the sale of its China subsidiary and secured over $30 million in follow-on defense-related orders.
Term
Q1 2027
“Fiscal 2027 is off to a strong start, led by backlog, a key indicator of our expected future revenue trends. New orders significantly outpaced shipments during the first quarter, lifting backlog by $22 million to a record $132.9 million, with approximately $110.8 million of it requested by customers for delivery over the next twelve months.”
Sam Rubin, President and Chief Executive Officer
“The composition of our revenue continues to be more favorable as well. Revenue grew 38% year-over-year to $20.8 million, and assemblies and modules accounted for 51% of the total, up from 40% a year ago. That shift toward higher-value cameras and optical assemblies lifted gross margin to 41.4%, and we generated positive adjusted EBITDA for the fifth consecutive quarter while more than doubling our investment in new product development.”
National CineMedia reported a net loss of $17.2 million for the third quarter of 2026, compared to a net income of $1.6 million in the prior year period, primarily driven by a $36.4 million loss on the re-measurement of the tax receivable agreement. The company significantly expanded its balance sheet through a $271.1 million business acquisition funded by a new $275.0 million term loan facility.
Black Rock Coffee Bar reported Q3 2026 revenue of $66.8 million, a 29.7% increase year-over-year, driven by 5.8% same-store sales growth and 11 new store openings. The company achieved net income of $2.7 million, a significant turnaround from a $16.2 million net loss in the prior year period. Management updated its full-year development target to 40 new store openings while reaffirming its revenue and Adjusted EBITDA guidance.
Term
Q3 2026
“We delivered another exceptional quarter, with revenue increasing 30% and adjusted EBITDA growing 22% year-over-year, reflecting the continued strength of our brand, customer engagement strategy and operating model. Same-store sales accelerated to 5.8%, or 16.6% on a two-year basis, marking our 15th consecutive quarter of positive same-store sales growth, while positive transaction growth reinforced our confidence in the resilience of consumer demand and the momentum we are building across the business.”
Vroom, Inc. reported its third quarter 2026 financial results, highlighting a net loss of $9.8 million and a stockholders' equity position of $91.1 million. The company updated its full-year 2026 guidance, projecting indirect origination volume between $460 million and $485 million and an adjusted net loss of $30 million to $35 million.
Term
Q3 2026
“In the third quarter of 2026, adjusted net loss improved significantly year-over-year as we continue to see the benefits of our rebuilt internal customer scoring model, which was implemented in September 2025. We also continue to make significant investments in our Next-Generation Technology Platform and we are pleased with the rollout of our Next-Generation FastLane dealer portal.”
Tom Shortt, Chief Executive Officer
“During the third quarter, we further strengthened our balance she”
Grayscale Sui Staking ETF reported net assets of $46.076 million as of September 30, 2026, a significant increase from $4.301 million at the end of 2025, driven by $33.7 million in net capital contributions and $8.067 million in net increase from operations. The Trust successfully uplisted to NYSE Arca on February 18, 2026, and began generating staking reward income, which totaled $246,000 for the first nine months of 2026.
Mobile Infrastructure Corp reported a net loss of $2.55 million for the quarter ended September 30, 2026, an improvement from a $6.43 million loss in the prior year period. Total revenues increased slightly to $9.58 million, driven by growth in managed property revenue, while total operating expenses decreased significantly due to lower depreciation and impairment charges.
For the third quarter of 2026, Grove Collaborative reported net revenue of $36.8 million and achieved a small net income of $0.1 million, a significant improvement from the $3.0 million net loss in the prior year period. The company reduced operating expenses across advertising and SG&A, though it continues to carry a total stockholders' deficit of $16.9 million.
Metagenomi Therapeutics, Inc. is an emerging growth company focused on genome editing technology, reporting 37,805,669 shares of common stock outstanding as of November 6, 2026. The filing highlights ongoing research and development programs, preclinical proof-of-concept goals, and risks related to macroeconomic volatility and regulatory developments.
QT Imaging Holdings reported significant revenue growth for the nine months ended September 30, 2026, reaching $21.3 million compared to $10.7 million in 2025. Despite this, the company incurred a net loss of $14.8 million, driven by increased operating expenses and a $8.3 million loss on debt extinguishment and modification.
SenesTech reported record third quarter 2026 revenue of $1.1 million, representing 59% year-over-year growth driven by a 337% surge in e-commerce sales. While gross profit reached a record $796,000 with a 72.6% margin, the company reported a net loss of $2.0 million for the quarter. Operational highlights include the expansion of the B2B sales team and the launch of new assessment and monitoring services for commercial customers.
For the nine months ended September 30, 2026, Grayscale Stellar Lumens Trust reported a net increase in net assets resulting from operations of $2.879 million, driven by $3.313 million in unrealized appreciation despite a net investment loss of $396,000. Total net assets grew to $26.848 million as of September 30, 2026, supported by capital share transactions and an increase in the Principal Market NAV per Share from $16.69 to $18.63.
QumulusAI, Inc. is a non-accelerated filer and emerging growth company that recently transitioned to public reporting, as evidenced by its 2026 filing. The company operates in the GPU-as-a-service and blockchain mining sectors, reporting significant risks including a history of losses, substantial indebtedness, and reliance on a single channel partner for GPU revenue.